Pregnancy is a hemodynamic challenge for the maternal cardiovascular system, particularly in women with preexisting cardiovascular heart diseases. Abnormal total peripheral vascular resistance (TPVR) and cardiac output (CO) precede maternal–fetal complications such as preeclampsia, fetal growth restriction, and abruptio placentae. A comprehensive evaluation before conception—including history, echocardiography, and stress testing—helps identify patients at highest risk and allows specific prepregnancy lifestyle interventions (such as exercise) and tailored pharmacotherapy. During gestation, serial cardiovascular assessments, including blood pressure, CO, TPVR, and left ventricular geometry, may guide hemodynamic-driven antihypertensive therapy. Early recognition of hypodynamic (high TPVR/low CO) or hyperdynamic (low TPVR/high CO) circulatory profiles allows the selection of agents—beta-blockers, calcium-channel blockers, or α-methyldopa—that target the underlying mechanism rather than pressure alone. Postpartum, women who experienced hypertensive disorders face elevated long-term risks of hypertension, heart failure, coronary artery disease, and stroke. Structured follow-up at 1, 6, and 12 months, and annually thereafter for high-risk patients, enables early detection of persistent cardiac dysfunction and modifiable risk factors. An interdisciplinary model uniting cardiologists and obstetricians ensures that hemodynamic insights translate into safer pregnancies and improved lifelong cardiovascular health.